Neal Flomenberg Sells 232,968 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 232,968 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $1.09, for a total transaction of $253,935.12. Following the completion of the sale, the insider now owns 3,595,608 shares of the company’s stock, valued at approximately $3,919,212.72. This trade represents a 6.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Neal Flomenberg also recently made the following trade(s):

• On Monday, March 10th, Neal Flomenberg sold 70,384 shares of Tevogen Bio stock. The shares were sold at an average price of $1.09, for a total transaction of $76,718.56.
• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90.
• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The shares were sold at an average price of $1.28, for a total transaction of $18,737.92.

Tevogen Bio Trading Up 5.4 %

Tevogen Bio stock opened at $1.17 on Monday. The firm’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.18. Tevogen Bio Holdings Inc. has a twelve month low of $0.26 and a twelve month high of $6.25.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its stake in Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after buying an additional 12,847 shares during the period. Northern Trust Corp increased its stake in Tevogen Bio by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after buying an additional 13,595 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after purchasing an additional 16,695 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Tevogen Bio during the 4th quarter worth $38,000. Finally, XTX Topco Ltd acquired a new position in shares of Tevogen Bio during the 4th quarter worth $55,000.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Tevogen Bio in a research report on Tuesday, March 11th.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.